Efficacy and Safety of Intravitreal Vascular Endothelial Growth Factor Trap-eye in Patients With Polyploidal Choroidal Vasculopathy

• Status: Completed
• Trial end date: 2017-11-02
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the efficacy and safety of aflibercept for treatment of polypoidal choroidal vasculopathy without active polyp.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Samsung Medical Center
• Collaborators: Bayer; Kim's Eye Hospital; Seoul National University Bundang Hospital
• Treatments: Aflibercept; Endothelial Growth Factors

Criteria

Inclusion Criteria:

• polypoidal choroidal vasculopathy without active polyp

• decreased visual acuity by subretinal fluid and hemorrhage involving foveal center

Exclusion Criteria:

• polypoidal choroidal vasculopathy with active polyp

• previous photodynamic therapy more than three times

• anti-VEGF injection within one month

• photodynamic therapy or intraocular steroid treatment within three months